Crossmark

Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria

Crossref DOI link: https://doi.org/10.1136/jitc-2024-010035

Published Online: 2025-01-16

Published Print: 2025-01

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Li, Lixing

Xu, Xin

Wang, Wentao

Huang, Peiran

Yu, Lei

Ren, Zhenggang

Fan, Jia

Zhou, Jian

Zhang, Lan

Wang, Zheng https://orcid.org/0000-0003-4838-0965
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04842565 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety and efficacy of PD-1 inhibitor (sintilimab) combined with transarterial chemoembolization as the initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria
https://doi.org/10.1136/jitc-2024-010035
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82173261)
License Information

License valid from 2025-01-16

Document is current

Any future updates will be listed below